Her research interests focus on HIV prevention strategies, including HIV pre-exposure prophylaxis and prevention and treatment of sexually-transmitted infections. She has led multi-center HIV prevention efficacy trials, including genital herpes suppression for prevention of HIV acquisition as well as HIV transmission. She co-led the Partners PrEP Study, which demonstrated high efficacy of tenofovir and emtricitabine-tenofovir prophylaxis, which contributed to FDA approval of PrEP for HIV prevention. Currently Dr. Celum’s research is focusing on implementation science research about PrEP implementation and STI interventions for young African women and MSM in the US. She is the co-Principal Investigator for the DoxyPEP study to evaluate doxycycline post-exposure prophylaxis for MSM and TGW living with HIV and on PrEP.